Patrys Ltd. has extended its relationship with Laureate Biopharmaceutical Services, Inc., to manufacture its lead product PAT-LM1 for preclinical and clinical use. PAT-LM1 is a human antibody that has been shown to have anti-cancer properties in animal models, including pancreatic, lung and colon cancers. Patrys has an existing arrangement with Laureate for the production of another anti-cancer product PAT-SM6, which is currently being evaluated in a clinical trial in patients with melanoma. “...